Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 3 2Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 2Sarcoma 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

Rituximab 238Cyclophosphamide 192Vincristine 164Doxorubicin 150Prednisone 126Methotrexate 80Cytarabine 79Etoposide 78Dexamethasone 72Radiotherapy 60Bendamustine Hydrochloride 58Mercaptopurine 46Lenalidomide 42pegaspargase 41Prednisolone 38Filgrastim 38ibrutinib 37fludarabine 36Bleomycin 36Daunorubicin 35obinutuzumab 34Asparaginase 33Leucovorin 29venetoclax 28Granulocyte Colony-Stimulating Factor 28Chlorambucil 27Calcium Dobesilate 27Gemcitabine 26Vinblastine 25Thioguanine 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × olverembatinib × Lymphoid × Clear all
NCT06051409 2026-04-30

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Ascentage Pharma Group Inc.

Phase 3 Recruiting
350 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07152041 2025-09-03

CAMS-Ph+ B-ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 3 Recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡